Table 2 Open in new tab Procedural...

After TAVR	Total	Isolated AS	MAVD	P value
NT-proBNP pg/mL median with inter-quartile ranges	1071.50 (957–1218)	1636 (1324–1958)	1752.50 (1541–933)	P = 0.673
AVmean mmHG	11.94 ± 6.34	12.11 ± 7.14	11.71 ± 6.09	P = 0.518
LA after TAVR	60.42 ± 8.79	59.50 ± 0.87	60.51 ± 9.32	P = 0.854
RA after TAVR	58.21 ± 8.58	58 ± 0.95	57.86 ± 8.88	P = 0.028
LVEDD after TAVR	44.66 ± 6.53	46 ± 0.74	44.29 ± 6.49	P = 0.414
RVEDD after TAVR	33.61 ± 5.85	34 ± 0.79	33.53 ± 5.85	P = 0.234
IVS after TAVR	14.42 ± 4.85	14 ± 0.23	14.56 ± 5.49	P = 0.461
MR after TAVR
MR ≥ II°	79 (8.98%)	17 (7.29%)	62 (9.58%)	P = 0.882
TR after TAVR
TR ≥ II°	132 (15%)	25 (10.73%)	107 (16.54%)	P = 0.544
Balloon-expandable valve	546 (62.04%)	109 (46.78%)	399 (61.67%)	P = <0.001
Edwars Sapien (1st gen)	8 (0.91%)	0 (0%)	8 (1.24%)	P = 0.088
Edwards Sapien XT	111 (12.61%)	9 (3.86%)	102 (15.77%)	P = <0.001
Edwards Sapien 3	362 (41.14%)	91 (39.06%)	271 (41.86%)	P = 0.452
Medtronic Evolut Pro	129 (14.66%)	44 (18.88%)	85 (13.14%)	P = 0.33
Acurate Neo	158 (17.95%)	40 (17.17%)	118 (18.24%)	P = 0.715
Valve size (mm)
20	4 (0.45%)	1 (0.43%)	3 (0.46%)	P = 0.941
23	193 (21.93%)	39 (16.74%)	154 (23.80%)	P = 0.022
25	87 (9.89%)	24 (10.30%)	63 (9.74%)	P = 0.834
26	260 (29.55%)	60 (25.75%)	200 (30.91%)	P = 0.120
27	92 (10.45%)	35 (15.02%)	57 (8.81%)	P = 0.009
29	188 (21.36%)	53 (22.75%)	135 (20.87%)	P = 0.587
31	4 (0.45%)	2 (0.86%)	2 (0.31%)	P = 0.290
34	39 (4.43%)	17 (7.29%)	22 (3.40%)	P = 0.014
Access route transfemoral	880 (100%)	233 (100%)	647 (100%)
Valve in valve procedure	39 (22.56%)	15 (6.44%)	24 (3.71%)	P = 0.669
Proglide vascular closure system	613 (69.66%)	248 (106.44%)	365 (56.41%)	P = <0.001
Manta vascular closure system	88 (10.0%)	38 (16.31%)	50 (7.73%)	P = 0.182
Sheath size 14	326 (37.05%)	113 (48.50%)	213 (32.92%)	P = 0.721
Sheath size 16	233 (226.48%)	57 (24.46%)	176 (27.20%)	P = <0.001
Acute kidney failure	87 (9.89%)	36 (15.45%)	51 (7.88%)	P = 0.254
Major vascular complication	52 (5.91%)	15 (6.44%)	37 (5.72%)	P = 0.286
Disabling stroke	19 (2.16%)	11 (4.72%)	8 (1.24%)	P = 0.005
PM after TAVR	106 (12.05%)	32 (13.73%)	74 (11.44%)	P = 0.289
Occurrence of PVR numerically
0°	149 (16.93%)	74 (31.76%)	75 (1.55%)	P = <0.001
I° (0.5–1)	436 (49.55%)	100 (42.92%)	336 (51.93%)	P = 0.011
II° (1.5–2)	147 (16.70%)	34 (14.59%)	113 (17.47%)	P = 0.289
III° (2.5–3)	10 (1.14%)	2 (0.86%)	8 (1.24%)	P = 0.633
Occurrence of PVR
	OR	95% CI	P value
In MAVD	2.058	1.505–2.814	P = <0.001
In isolated AS	0.486	0.355–0.664	P = <0.001

After TAVR

Total

Isolated AS

MAVD

P value

(n = 880)

(n = 233, 26.48%)

(n = 647, 73.5%)

NT-proBNP pg/mL median with inter-quartile ranges

1071.50 (957–1218)

1636 (1324–1958)

1752.50 (1541–933)

P = 0.673

AVmean mmHG

11.94 ± 6.34

12.11 ± 7.14

11.71 ± 6.09

P = 0.518

LA after TAVR

60.42 ± 8.79

59.50 ± 0.87

60.51 ± 9.32

P = 0.854

RA after TAVR

58.21 ± 8.58

58 ± 0.95

57.86 ± 8.88

P = 0.028

LVEDD after TAVR

44.66 ± 6.53

46 ± 0.74

44.29 ± 6.49

P = 0.414

RVEDD after TAVR

33.61 ± 5.85

34 ± 0.79

33.53 ± 5.85

P = 0.234

IVS after TAVR

14.42 ± 4.85

14 ± 0.23

14.56 ± 5.49

P = 0.461

MR after TAVR

MR ≥ II°

79 (8.98%)

17 (7.29%)

62 (9.58%)

P = 0.882

TR after TAVR

TR ≥ II°

132 (15%)

25 (10.73%)

107 (16.54%)

P = 0.544

Balloon-expandable valve

546 (62.04%)

109 (46.78%)

399 (61.67%)

P = <0.001

Edwars Sapien (1st gen)

8 (0.91%)

0 (0%)

8 (1.24%)

P = 0.088

Edwards Sapien XT

111 (12.61%)

9 (3.86%)

102 (15.77%)

P = <0.001

Edwards Sapien 3

362 (41.14%)

91 (39.06%)

271 (41.86%)

P = 0.452

Medtronic Evolut Pro

129 (14.66%)

44 (18.88%)

85 (13.14%)

P = 0.33

Acurate Neo

158 (17.95%)

40 (17.17%)

118 (18.24%)

P = 0.715

Valve size (mm)

4 (0.45%)

1 (0.43%)

3 (0.46%)

P = 0.941

193 (21.93%)

39 (16.74%)

154 (23.80%)

P = 0.022

87 (9.89%)

24 (10.30%)

63 (9.74%)

P = 0.834

260 (29.55%)

60 (25.75%)

200 (30.91%)

P = 0.120

92 (10.45%)

35 (15.02%)

57 (8.81%)

P = 0.009

188 (21.36%)

53 (22.75%)

135 (20.87%)

P = 0.587

4 (0.45%)

2 (0.86%)

2 (0.31%)

P = 0.290

39 (4.43%)

17 (7.29%)

22 (3.40%)

P = 0.014

Access route transfemoral

880 (100%)

233 (100%)

647 (100%)

Valve in valve procedure

39 (22.56%)

15 (6.44%)

24 (3.71%)

P = 0.669

Proglide vascular closure system

613 (69.66%)

248 (106.44%)

365 (56.41%)

P = <0.001

Manta vascular closure system

88 (10.0%)

38 (16.31%)

50 (7.73%)

P = 0.182

Sheath size 14

326 (37.05%)

113 (48.50%)

213 (32.92%)

P = 0.721

Sheath size 16

233 (226.48%)

57 (24.46%)

176 (27.20%)

P = <0.001

Acute kidney failure

87 (9.89%)

36 (15.45%)

51 (7.88%)

P = 0.254

Major vascular complication

52 (5.91%)

15 (6.44%)

37 (5.72%)

P = 0.286

Disabling stroke

19 (2.16%)

11 (4.72%)

8 (1.24%)

P = 0.005

PM after TAVR

106 (12.05%)

32 (13.73%)

74 (11.44%)

P = 0.289

Occurrence of PVR numerically

0°

149 (16.93%)

74 (31.76%)

75 (1.55%)

P = <0.001

I° (0.5–1)

436 (49.55%)

100 (42.92%)

336 (51.93%)

P = 0.011

II° (1.5–2)

147 (16.70%)

34 (14.59%)

113 (17.47%)

P = 0.289

III° (2.5–3)

10 (1.14%)

2 (0.86%)

8 (1.24%)

P = 0.633

Occurrence of PVR

95% CI

P value

In MAVD

2.058

1.505–2.814

P = <0.001

In isolated AS

0.486

0.355–0.664

P = <0.001

After TAVR	Total	Isolated AS	MAVD	P value
NT-proBNP pg/mL median with inter-quartile ranges	1071.50 (957–1218)	1636 (1324–1958)	1752.50 (1541–933)	P = 0.673
AVmean mmHG	11.94 ± 6.34	12.11 ± 7.14	11.71 ± 6.09	P = 0.518
LA after TAVR	60.42 ± 8.79	59.50 ± 0.87	60.51 ± 9.32	P = 0.854
RA after TAVR	58.21 ± 8.58	58 ± 0.95	57.86 ± 8.88	P = 0.028
LVEDD after TAVR	44.66 ± 6.53	46 ± 0.74	44.29 ± 6.49	P = 0.414
RVEDD after TAVR	33.61 ± 5.85	34 ± 0.79	33.53 ± 5.85	P = 0.234
IVS after TAVR	14.42 ± 4.85	14 ± 0.23	14.56 ± 5.49	P = 0.461
MR after TAVR
MR ≥ II°	79 (8.98%)	17 (7.29%)	62 (9.58%)	P = 0.882
TR after TAVR
TR ≥ II°	132 (15%)	25 (10.73%)	107 (16.54%)	P = 0.544
Balloon-expandable valve	546 (62.04%)	109 (46.78%)	399 (61.67%)	P = <0.001
Edwars Sapien (1st gen)	8 (0.91%)	0 (0%)	8 (1.24%)	P = 0.088
Edwards Sapien XT	111 (12.61%)	9 (3.86%)	102 (15.77%)	P = <0.001
Edwards Sapien 3	362 (41.14%)	91 (39.06%)	271 (41.86%)	P = 0.452
Medtronic Evolut Pro	129 (14.66%)	44 (18.88%)	85 (13.14%)	P = 0.33
Acurate Neo	158 (17.95%)	40 (17.17%)	118 (18.24%)	P = 0.715
Valve size (mm)
20	4 (0.45%)	1 (0.43%)	3 (0.46%)	P = 0.941
23	193 (21.93%)	39 (16.74%)	154 (23.80%)	P = 0.022
25	87 (9.89%)	24 (10.30%)	63 (9.74%)	P = 0.834
26	260 (29.55%)	60 (25.75%)	200 (30.91%)	P = 0.120
27	92 (10.45%)	35 (15.02%)	57 (8.81%)	P = 0.009
29	188 (21.36%)	53 (22.75%)	135 (20.87%)	P = 0.587
31	4 (0.45%)	2 (0.86%)	2 (0.31%)	P = 0.290
34	39 (4.43%)	17 (7.29%)	22 (3.40%)	P = 0.014
Access route transfemoral	880 (100%)	233 (100%)	647 (100%)
Valve in valve procedure	39 (22.56%)	15 (6.44%)	24 (3.71%)	P = 0.669
Proglide vascular closure system	613 (69.66%)	248 (106.44%)	365 (56.41%)	P = <0.001
Manta vascular closure system	88 (10.0%)	38 (16.31%)	50 (7.73%)	P = 0.182
Sheath size 14	326 (37.05%)	113 (48.50%)	213 (32.92%)	P = 0.721
Sheath size 16	233 (226.48%)	57 (24.46%)	176 (27.20%)	P = <0.001
Acute kidney failure	87 (9.89%)	36 (15.45%)	51 (7.88%)	P = 0.254
Major vascular complication	52 (5.91%)	15 (6.44%)	37 (5.72%)	P = 0.286
Disabling stroke	19 (2.16%)	11 (4.72%)	8 (1.24%)	P = 0.005
PM after TAVR	106 (12.05%)	32 (13.73%)	74 (11.44%)	P = 0.289
Occurrence of PVR numerically
0°	149 (16.93%)	74 (31.76%)	75 (1.55%)	P = <0.001
I° (0.5–1)	436 (49.55%)	100 (42.92%)	336 (51.93%)	P = 0.011
II° (1.5–2)	147 (16.70%)	34 (14.59%)	113 (17.47%)	P = 0.289
III° (2.5–3)	10 (1.14%)	2 (0.86%)	8 (1.24%)	P = 0.633
Occurrence of PVR
	OR	95% CI	P value
In MAVD	2.058	1.505–2.814	P = <0.001
In isolated AS	0.486	0.355–0.664	P = <0.001

After TAVR

Total

Isolated AS

MAVD

P value

(n = 880)

(n = 233, 26.48%)

(n = 647, 73.5%)

NT-proBNP pg/mL median with inter-quartile ranges

1071.50 (957–1218)

1636 (1324–1958)

1752.50 (1541–933)

P = 0.673

AVmean mmHG

11.94 ± 6.34

12.11 ± 7.14

11.71 ± 6.09

P = 0.518

LA after TAVR

60.42 ± 8.79

59.50 ± 0.87

60.51 ± 9.32

P = 0.854

RA after TAVR

58.21 ± 8.58

58 ± 0.95

57.86 ± 8.88

P = 0.028

LVEDD after TAVR

44.66 ± 6.53

46 ± 0.74

44.29 ± 6.49

P = 0.414

RVEDD after TAVR

33.61 ± 5.85

34 ± 0.79

33.53 ± 5.85

P = 0.234

IVS after TAVR

14.42 ± 4.85

14 ± 0.23

14.56 ± 5.49

P = 0.461

MR after TAVR

MR ≥ II°

79 (8.98%)

17 (7.29%)

62 (9.58%)

P = 0.882

TR after TAVR

TR ≥ II°

132 (15%)

25 (10.73%)

107 (16.54%)

P = 0.544

Balloon-expandable valve

546 (62.04%)

109 (46.78%)

399 (61.67%)

P = <0.001

Edwars Sapien (1st gen)

8 (0.91%)

0 (0%)

8 (1.24%)

P = 0.088

Edwards Sapien XT

111 (12.61%)

9 (3.86%)

102 (15.77%)

P = <0.001

Edwards Sapien 3

362 (41.14%)

91 (39.06%)

271 (41.86%)

P = 0.452

Medtronic Evolut Pro

129 (14.66%)

44 (18.88%)

85 (13.14%)

P = 0.33

Acurate Neo

158 (17.95%)

40 (17.17%)

118 (18.24%)

P = 0.715

Valve size (mm)

4 (0.45%)

1 (0.43%)

3 (0.46%)

P = 0.941

193 (21.93%)

39 (16.74%)

154 (23.80%)

P = 0.022

87 (9.89%)

24 (10.30%)

63 (9.74%)

P = 0.834

260 (29.55%)

60 (25.75%)

200 (30.91%)

P = 0.120

92 (10.45%)

35 (15.02%)

57 (8.81%)

P = 0.009

188 (21.36%)

53 (22.75%)

135 (20.87%)

P = 0.587

4 (0.45%)

2 (0.86%)

2 (0.31%)

P = 0.290

39 (4.43%)

17 (7.29%)

22 (3.40%)

P = 0.014

Access route transfemoral

880 (100%)

233 (100%)

647 (100%)

Valve in valve procedure

39 (22.56%)

15 (6.44%)

24 (3.71%)

P = 0.669

Proglide vascular closure system

613 (69.66%)

248 (106.44%)

365 (56.41%)

P = <0.001

Manta vascular closure system

88 (10.0%)

38 (16.31%)

50 (7.73%)

P = 0.182

Sheath size 14

326 (37.05%)

113 (48.50%)

213 (32.92%)

P = 0.721

Sheath size 16

233 (226.48%)

57 (24.46%)

176 (27.20%)

P = <0.001

Acute kidney failure

87 (9.89%)

36 (15.45%)

51 (7.88%)

P = 0.254

Major vascular complication

52 (5.91%)

15 (6.44%)

37 (5.72%)

P = 0.286

Disabling stroke

19 (2.16%)

11 (4.72%)

8 (1.24%)

P = 0.005

PM after TAVR

106 (12.05%)

32 (13.73%)

74 (11.44%)

P = 0.289

Occurrence of PVR numerically

0°

149 (16.93%)

74 (31.76%)

75 (1.55%)

P = <0.001

I° (0.5–1)

436 (49.55%)

100 (42.92%)

336 (51.93%)

P = 0.011

II° (1.5–2)

147 (16.70%)

34 (14.59%)

113 (17.47%)

P = 0.289

III° (2.5–3)

10 (1.14%)

2 (0.86%)

8 (1.24%)

P = 0.633

Occurrence of PVR

95% CI

P value

In MAVD

2.058

1.505–2.814

P = <0.001

In isolated AS

0.486

0.355–0.664

P = <0.001

Table 2

Open in new tab

Procedural characteristics

After TAVR	Total	Isolated AS	MAVD	P value
After TAVR	(n = 880)	(n = 233, 26.48%)	(n = 647, 73.5%)	P value
NT-proBNP pg/mL median with inter-quartile ranges	1071.50 (957–1218)	1636 (1324–1958)	1752.50 (1541–933)	P = 0.673
AVmean mmHG	11.94 ± 6.34	12.11 ± 7.14	11.71 ± 6.09	P = 0.518
LA after TAVR	60.42 ± 8.79	59.50 ± 0.87	60.51 ± 9.32	P = 0.854
RA after TAVR	58.21 ± 8.58	58 ± 0.95	57.86 ± 8.88	P = 0.028
LVEDD after TAVR	44.66 ± 6.53	46 ± 0.74	44.29 ± 6.49	P = 0.414
RVEDD after TAVR	33.61 ± 5.85	34 ± 0.79	33.53 ± 5.85	P = 0.234
IVS after TAVR	14.42 ± 4.85	14 ± 0.23	14.56 ± 5.49	P = 0.461
MR after TAVR
MR ≥ II°	79 (8.98%)	17 (7.29%)	62 (9.58%)	P = 0.882
TR after TAVR
TR ≥ II°	132 (15%)	25 (10.73%)	107 (16.54%)	P = 0.544
Balloon-expandable valve	546 (62.04%)	109 (46.78%)	399 (61.67%)	P = <0.001
Edwars Sapien (1st gen)	8 (0.91%)	0 (0%)	8 (1.24%)	P = 0.088
Edwards Sapien XT	111 (12.61%)	9 (3.86%)	102 (15.77%)	P = <0.001
Edwards Sapien 3	362 (41.14%)	91 (39.06%)	271 (41.86%)	P = 0.452
Medtronic Evolut Pro	129 (14.66%)	44 (18.88%)	85 (13.14%)	P = 0.33
Acurate Neo	158 (17.95%)	40 (17.17%)	118 (18.24%)	P = 0.715
Valve size (mm)
20	4 (0.45%)	1 (0.43%)	3 (0.46%)	P = 0.941
23	193 (21.93%)	39 (16.74%)	154 (23.80%)	P = 0.022
25	87 (9.89%)	24 (10.30%)	63 (9.74%)	P = 0.834
26	260 (29.55%)	60 (25.75%)	200 (30.91%)	P = 0.120
27	92 (10.45%)	35 (15.02%)	57 (8.81%)	P = 0.009
29	188 (21.36%)	53 (22.75%)	135 (20.87%)	P = 0.587
31	4 (0.45%)	2 (0.86%)	2 (0.31%)	P = 0.290
34	39 (4.43%)	17 (7.29%)	22 (3.40%)	P = 0.014
Access route transfemoral	880 (100%)	233 (100%)	647 (100%)
Valve in valve procedure	39 (22.56%)	15 (6.44%)	24 (3.71%)	P = 0.669
Proglide vascular closure system	613 (69.66%)	248 (106.44%)	365 (56.41%)	P = <0.001
Manta vascular closure system	88 (10.0%)	38 (16.31%)	50 (7.73%)	P = 0.182
Sheath size 14	326 (37.05%)	113 (48.50%)	213 (32.92%)	P = 0.721
Sheath size 16	233 (226.48%)	57 (24.46%)	176 (27.20%)	P = <0.001
Acute kidney failure	87 (9.89%)	36 (15.45%)	51 (7.88%)	P = 0.254
Major vascular complication	52 (5.91%)	15 (6.44%)	37 (5.72%)	P = 0.286
Disabling stroke	19 (2.16%)	11 (4.72%)	8 (1.24%)	P = 0.005
PM after TAVR	106 (12.05%)	32 (13.73%)	74 (11.44%)	P = 0.289
Occurrence of PVR numerically
0°	149 (16.93%)	74 (31.76%)	75 (1.55%)	P = <0.001
I° (0.5–1)	436 (49.55%)	100 (42.92%)	336 (51.93%)	P = 0.011
II° (1.5–2)	147 (16.70%)	34 (14.59%)	113 (17.47%)	P = 0.289
III° (2.5–3)	10 (1.14%)	2 (0.86%)	8 (1.24%)	P = 0.633
Occurrence of PVR
	OR	95% CI	P value
In MAVD	2.058	1.505–2.814	P = <0.001
In isolated AS	0.486	0.355–0.664	P = <0.001

After TAVR	Total	Isolated AS	MAVD	P value
After TAVR	(n = 880)	(n = 233, 26.48%)	(n = 647, 73.5%)	P value
NT-proBNP pg/mL median with inter-quartile ranges	1071.50 (957–1218)	1636 (1324–1958)	1752.50 (1541–933)	P = 0.673
AVmean mmHG	11.94 ± 6.34	12.11 ± 7.14	11.71 ± 6.09	P = 0.518
LA after TAVR	60.42 ± 8.79	59.50 ± 0.87	60.51 ± 9.32	P = 0.854
RA after TAVR	58.21 ± 8.58	58 ± 0.95	57.86 ± 8.88	P = 0.028
LVEDD after TAVR	44.66 ± 6.53	46 ± 0.74	44.29 ± 6.49	P = 0.414
RVEDD after TAVR	33.61 ± 5.85	34 ± 0.79	33.53 ± 5.85	P = 0.234
IVS after TAVR	14.42 ± 4.85	14 ± 0.23	14.56 ± 5.49	P = 0.461
MR after TAVR
MR ≥ II°	79 (8.98%)	17 (7.29%)	62 (9.58%)	P = 0.882
TR after TAVR
TR ≥ II°	132 (15%)	25 (10.73%)	107 (16.54%)	P = 0.544
Balloon-expandable valve	546 (62.04%)	109 (46.78%)	399 (61.67%)	P = <0.001
Edwars Sapien (1st gen)	8 (0.91%)	0 (0%)	8 (1.24%)	P = 0.088
Edwards Sapien XT	111 (12.61%)	9 (3.86%)	102 (15.77%)	P = <0.001
Edwards Sapien 3	362 (41.14%)	91 (39.06%)	271 (41.86%)	P = 0.452
Medtronic Evolut Pro	129 (14.66%)	44 (18.88%)	85 (13.14%)	P = 0.33
Acurate Neo	158 (17.95%)	40 (17.17%)	118 (18.24%)	P = 0.715
Valve size (mm)
20	4 (0.45%)	1 (0.43%)	3 (0.46%)	P = 0.941
23	193 (21.93%)	39 (16.74%)	154 (23.80%)	P = 0.022
25	87 (9.89%)	24 (10.30%)	63 (9.74%)	P = 0.834
26	260 (29.55%)	60 (25.75%)	200 (30.91%)	P = 0.120
27	92 (10.45%)	35 (15.02%)	57 (8.81%)	P = 0.009
29	188 (21.36%)	53 (22.75%)	135 (20.87%)	P = 0.587
31	4 (0.45%)	2 (0.86%)	2 (0.31%)	P = 0.290
34	39 (4.43%)	17 (7.29%)	22 (3.40%)	P = 0.014
Access route transfemoral	880 (100%)	233 (100%)	647 (100%)
Valve in valve procedure	39 (22.56%)	15 (6.44%)	24 (3.71%)	P = 0.669
Proglide vascular closure system	613 (69.66%)	248 (106.44%)	365 (56.41%)	P = <0.001
Manta vascular closure system	88 (10.0%)	38 (16.31%)	50 (7.73%)	P = 0.182
Sheath size 14	326 (37.05%)	113 (48.50%)	213 (32.92%)	P = 0.721
Sheath size 16	233 (226.48%)	57 (24.46%)	176 (27.20%)	P = <0.001
Acute kidney failure	87 (9.89%)	36 (15.45%)	51 (7.88%)	P = 0.254
Major vascular complication	52 (5.91%)	15 (6.44%)	37 (5.72%)	P = 0.286
Disabling stroke	19 (2.16%)	11 (4.72%)	8 (1.24%)	P = 0.005
PM after TAVR	106 (12.05%)	32 (13.73%)	74 (11.44%)	P = 0.289
Occurrence of PVR numerically
0°	149 (16.93%)	74 (31.76%)	75 (1.55%)	P = <0.001
I° (0.5–1)	436 (49.55%)	100 (42.92%)	336 (51.93%)	P = 0.011
II° (1.5–2)	147 (16.70%)	34 (14.59%)	113 (17.47%)	P = 0.289
III° (2.5–3)	10 (1.14%)	2 (0.86%)	8 (1.24%)	P = 0.633
Occurrence of PVR
	OR	95% CI	P value
In MAVD	2.058	1.505–2.814	P = <0.001
In isolated AS	0.486	0.355–0.664	P = <0.001

NT-proBNP, n-terminal pro–B-type natriuretic peptide; LA, left atrium; RA, right atrium; LVEDD, left ventricular end-diastolic diameter; RVEDD, right ventricular end-diastolic diameter; IVS, interventricular septum; MR, mitral regurgitation; TR, tricuspid regurgitation; PM, pacemaker; MAVD, mixed aortic valve disease; AS, aortic stenosis.

This Feature Is Available To Subscribers Only